

YPSOMED HOLDING AG

ISIN: CH0019396990 WKN: 1939699

Overview





Information about previous performance does not guarantee future performance. **Source:** FactSet

Recent research

on sector	on market		
Date		Headline	Download
2024/08/12	80 66 87 78	Global Equity Ratings	
2024/07/24	80 88 80 88	Global Equity Ratings	
2024/07/12	80 86 80 100	Global Equity Ratings	
2024/06/21	80 88 80 88	Global Equity Ratings	
2024/06/14	201 120 201 120	Global Equity Ratings	.≛.






Details



Market data	
Bid (Bid size)	-
Ask (Ask size)	-
Open	119.00 EUR
High	120.80 EUR
Low	119.00 EUR
Close (prev. day)	117.20 EUR
VWAP	-
Volume (pcs)	0
Trading volume	0.00
Number of trades	5
Last size	0

Performance and Risk				
	6m	1Y	3Y	
Perf (%)	+16.83%	-2.97%	-21.26%	
Perf (abs.)	+17.40	-3.70	-32.62	
Beta	0.50	0.70	0.88	
Volatility	26.32	23.72	29.99	



Information about previous performance does not guarantee future performance. **Source:** FactSet

Price data	
Ø price 5 days Ø volume 5 days (pcs.)	117.84 EUR (0)
Ø price 30 days Ø volume 30 days (pcs.)	112.34 EUR (0)
Ø price 100 days Ø volume 100 days (pcs.)	112.20 EUR (9)
Ø price 250 days Ø volume 250 days (pcs.)	115.27 EUR (5)
YTD High date	122.00 EUR (2019/05/22)
YTD Low date	99.00 EUR (2019/01/30)
52 Weeks High date	129.70 EUR (2018/08/30)
52 Weeks Low date	98.85 EUR (2018/12/21)

All listings for YPSOMED HOLDING AG					
Exchange 🖨	Date	Time	Price	Trading volume (mio.)	Number of trades
SIX Swiss Exchange	2024/08/ 16	17:31	411.00 CHF	1.46	237
London Stock Exchange	2024/05/ 21	16:12	339.50 CHF	0.16	1
Frankfurt	2019/06/ 28	15:43	120.60 EUR	0.00	3
FINRA other OTC Issues	2024/08/ 02	15:48	452.47 USD	0.00	1
Berlin	2019/06/	15:59	120.80 EUR	0.00	5





Company profile

Company Logo



Contact Details

YPSOMED HOLDING AG

_ _

Brunnmattstrasse 6 - 3401 Burgdorf

Telefon: +41-34-424-41-11

Fax: +

E-mail: info@ypsomed.com

PDF Downloads

Company report: YPSOMED HOLDING

AG

Company Profile

Ypsomed Holding AG engages in the development and manufacture of injection systems for self-medication of drugs by patients, most notably used to treat diabetes. It operates through the following segments: Ypsomed Diabetes Care, Ypsomed Delivery Systems, and Others. The Ypsomed Diabetes Care segment is involved in the products that are sold directly to hospitals, doctors, pharmacies, and patients via Ypsomed subsidiaries and distributors. The Ypsomed Delivery Systems segment focuses on the pharmaceutical and biotech customers with injection systems and related services. The Others segment consists of Ypsotec and properties not used for operational purposes. The company was founded by Wilhelm Michel on December 29, 2003, and is headquartered in Burgdorf, Switzerland.

Members of Management Board		
Simon Michel	Chairman of Managing Board	
Frank Mengis	Member of Executive Committee	
Michael Zaugg	Member of Executive Committee	
Niklaus Ramseier	Member of Executive Committee	
Sébastien Delarive	Member of Executive Committee	
Ulrike Bauer	Member of Executive Committee	

Board of directors		
Martin C. Münchbach	Member of the administrative board	
Betül Susamis Unaran	Member of the administrative board	
Paul R. Fonteyne	Member of the administrative board	
Gilbert Achermann	Chairman of the administrative boar	

